Can-Fite says Phase 2a pancreatic cancer data accepted for ESMO Congress 2026

Can-Fite BioPharma Ltd. announced on July 20, 2026 that an abstract covering its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC) has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The trial enrolled patients with advanced PDAC, and Can-Fite is a clinical-stage biotechnology company developing small molecule drugs for oncological and inflammatory diseases.¹

The accepted abstract carries the title "Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study."¹ The study tested oral Namodenoson in patients whose advanced pancreatic cancer had progressed after prior standard therapies.¹ According to the company, the trial met its primary safety goal, and patients showed survival results and disease stabilization that Can-Fite described as encouraging in this hard-to-treat group.

Company chairperson and chief scientific officer Pnina Fishman said the ESMO acceptance gives the pancreatic cancer program scientific recognition and a chance to share findings with the global oncology community.¹

Namodenoson works as a highly selective A3 adenosine receptor agonist that triggers cancer cell apoptosis, with anti-tumor activity shown in preclinical models including pancreatic cancer; it is also in development for hepatocellular carcinoma and MASH.¹ Can-Fite said it intends to move Namodenoson into a Phase 2b study pairing it with chemotherapy for pancreatic cancer, citing supportive clinical and preclinical data on combined anti-tumor effects. The company said further poster logistics, including the presentation date and poster number, will be released later.